Natera shares are trading higher after the company announced that its Signatera cancer testing technology was added to the National Comprehensive Cancer Network's oncology guidelines.

Benzinga Newsdesk www.benzinga.com Positive 94.1%

Neg 0% Neu 0% Pos 94.1%

Comments

No comments yet. Be the first!